Abstract The US Food and Drug administration (FDA) has approved several polyclonal
antibody preparations and at least 18 monoclonal antibody preparations (antibodies …

This review discusses the current state of biomarker discovery for the purposes of
diagnostics and therapeutic monitoring. We underscore relevant challenges that have …

Purpose: An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE)
conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties …

Purpose To compare low-dose (30 Gy) radiotherapy (RT) with observation (OBS) in limited-
stage aggressive lymphoma patients achieving complete remission (CR) after …

Background Auger electron emitters that can be targeted into DNA of tumour cells represent
an attractive systemic radiation therapy goal. In the situation of DNA-associated decay, the …

The present article highlights the important progress made in the last two decades in the
fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based …

New treatments are required for rituximab-refractory follicular lymphoma (FL). In the present
study, patients with rituximab-refractory FL received 8 weekly infusions of ofatumumab …

Recombinant antibodies currently represent over 30% of biopharmaceuticals in clinical
trials, highlighted by the recent Food and Drug Administration (FDA) approvals of …

Every day we, as cancer nurses, care for patients with life-threatening conditions, and every
day we are responsible for the delivery of complex treatments to our patients. We witness at …

Seventeen monoclonal antibodies are currently approved in the United States for
therapeutic use in organ transplantation, percutaneous coronary intervention, prophylaxis of …